Phase 2 Trial Of S-531011 With RadScopal In Previously Treated Metastatic Colorectal Cancer

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT07720115
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Metastatic Colorectal Cancer
  • Phase II
  • RadScopal
  • S-531011

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • S-531011 — DRUG
    Given by IV
  • HD-XRT — RADIATION
    Given by radiation

Study Details

To learn if the experimental drug S-531011 plus RadScopalTM radiation therapy can help to control previously treated metastatic colorectal cancer.

Key Dates

First listed
Jul 22, 2026
Start date
Jan 7, 2027
Status verified
Jul 2026
Primary completion
Jan 1, 2029
Completion
Jan 1, 2031

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment with S-531011 + RadScopal XRT

Primary Outcome Measure

safety and adverse events (AEs) [ Time Frame: Through study completion; an average of 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
MD Anderson Cancer CenterHoustonTexas77030
Daniel Haldar, MD
[email protected]
832-343-4973
Daniel Haldar, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By research site
MD Anderson Cancer Center· Houston, TX

Related Studies